REG - Provexis PLC - Final Results
Yesterday 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251030:nRSd4096Fa&default-theme=true
RNS Number : 4096F Provexis PLC 30 October 2025
30 October
2025
Provexis plc
("Provexis" or the "Company")
PRELIMINARY RESULTS for the YEAR ended 31 MARCH 2025
Provexis plc ('Provexis' or the 'Company'), the business that develops,
licenses and sells the proprietary, scientifically-proven Fruitflow®
heart-health functional food ingredient, announces its audited preliminary
results for the year ended 31 March 2025.
Key highlights
· Total revenue for the year of £1.29m (2024: £802k), a 61% year
on year increase, reflecting strongly increased demand from existing and new
customers for Fruitflow throughout the year.
· Total revenue includes £1.17m from Fruitflow II SD (2024:
£652k) and £121k (2024: £150k) from Fruitflow+ Omega-3.
· Provexis Ireland Limited, the Group's new Irish subsidiary
company, started trading in April 2024 from a fulfilment centre in the EU,
facilitating fast and tariff free sales of Fruitflow to customers in the EU.
· The new long term commercial partnership with dsm-firmenich
('DSM') has progressed well during the year, with continuing interest from
some significant global customers. The commercial partnership is based on: (i)
a Premix and Market-Ready Solutions supply agreement for Fruitflow II SD; and
(ii) the use of Fruitflow to confer health benefits in modulating the gut
microbiome of humans.
· Planned launch by BYHEALTH, a circa £2bn listed Chinese dietary
supplement business, of a number of Fruitflow based products in the Chinese
market, with potential sales volumes remaining at a significant multiple of
existing Fruitflow sales. BYHEALTH continues to work on an extensive
regulatory submission to the Chinese SAMR, seeking to establish a new
permitted health function claim for foods such as Fruitflow that can
demonstrate an anti-platelet effect. BYHEALTH has stated publicly that it has
invested 'tens of millions of funds' (RMB) in the research and development
work. The Company and BYHEALTH remain in close and constructive dialogue, at a
high level.
· Underlying operating loss* for the year of £278k (2024: £469k),
an improvement of £191k year on year.
· Cash of £708k at 31 March 2025 (2024: £189k).
*Loss from operations, adjusted for (i) share-based payments of £168k (2024:
£121k), and (ii) R&D tax relief: receivable tax credit of £6k (2024:
£14k).
Post year end
The Company also confirms that subsequent to the year end on 31 March 2025:
· All of the remaining Fruitflow II SD inventory which the Company
purchased from DSM in 2023 and 2024 has been sold, and the Company expects in
due course to report total sales for the six months ended 30 September 2025 in
excess of £350k.
· A new production run of Fruitflow II SD has been completed by the
Company's outsourced supply chain partners for Fruitflow; the Company has
received delivery of the new batch of Fruitflow II SD and is shipping the new
material out to customers.
· The Company expects to sell several hundred thousand pounds of
Fruitflow II SD in the quarter ended 31 December 2025, and is dealing with
numerous sales enquiries from existing and new customers for further direct
sales of Fruitflow in 2026 and beyond.
· In light of anticipated demand the Company is now planning with
its outsourced supply chain partners to undertake at least three further
production runs of Fruitflow II SD in the next twelve months.
Annual report and accounts and notice of AGM
The Company's annual report and accounts for the year ended 31 March 2025 and
the AGM notice will be available from the Shareholder information section of
the Company's website www.provexis.com (http://www.provexis.com) on 30 October
2025, and from the address below:
The Company Secretary
Provexis plc
2 Blagrave Street
Reading
RG1 1AZ
The Company's annual report and accounts and its AGM notice will be
distributed by post today to those shareholders who have elected to continue
to receive paper communications.
Proxy forms for use in connection with the AGM will also be distributed by
post today to all shareholders on the Company's share register.
The AGM will be held at 12:30pm on 21 November 2025 at the offices of Allenby
Capital Limited, 5th Floor, 5 St Helen's Place, London EC3A 6AB.
Following the publication of the Accounts this morning, the temporary
suspension of the Company's securities from trading on AIM is expected to be
lifted at 07:30am today, 30 October 2025.
For further information please contact:
Provexis plc Tel: 07490 391888
Ian Ford, CEO enquiries@provexis.com
Dawson Buck, Chairman
Allenby Capital Limited Tel: 020 3328 5656
Nick Naylor / Ashur Joseph
Chairman and CEO's statement
The Company has had a year of strong progress, to include a 61% year on year
increase in revenue, reflecting strongly increased demand throughout the year
from existing and new customers for Fruitflow II SD, the Company's innovative,
patented Fruitflow® heart-health ingredient.
DSM Nutritional Products - new agreements for Fruitflow®
Provexis entered into a long-term Alliance Agreement with DSM Nutritional
Products ('DSM'), which is part of DSM-Firmenich AG, in 2010 to commercialise
Fruitflow through sales as an ingredient to brand owners in the food, beverage
and dietary supplement categories, with a contractual term for the Alliance
Agreement which ran to 31 December 2022.
More than 100 regional consumer healthcare brands have now been launched by
direct customers of DSM, and a number of further regional brands have been
launched through DSM's distributor channels. An increasing number of
commercial projects have been initiated by DSM with prospective customers in
recent years, including some prospective customers which are part of global
businesses, and the total projected annual sales value of the prospective
sales pipeline for Fruitflow, which is now shared across Provexis and DSM,
continues to stand at a substantial multiple of existing annual sales.
In June 2022 Provexis announced it had secured two new agreements with DSM for
Fruitflow, to replace the Alliance Agreement: (i) a Transfer of Business
agreement; and (ii) a Premix and Market-Ready Solutions supply agreement,
which both took effect on 1 January 2023.
The Company also announced the filing of a new patent application in June 2022
relating to the use of Fruitflow to confer health benefits in modulating the
gut microbiome of humans. This followed the completion of a successful human
study, the results of which strongly support the use of Fruitflow for
modulating gut microbiota to confer a number of health benefits, to include a
reduction in TMAO (trimethylamine-n-oxide).
Under the terms of the two new agreements with DSM, and the June 2022 patent
application:
· DSM's existing and prospective customers for Fruitflow as a
straight ingredient (not a Premix or Market-Ready solution) transferred to
become direct customers of Provexis from 1 January 2023, and the Company took
over the wholly outsourced supply chain / production process for Fruitflow
from DSM at that time.
· A royalty is payable to DSM on the gross profits generated from
Fruitflow sales to customers transferred from DSM over the first four years of
the Transfer of Business agreement. The year ended 31 March 2025 included nine
months of the royalty payable to DSM at the second year rate to 31 December
2024, and three months of the royalty payable at the lower third year rate to
31 March 2025. The royalty will decrease further, and at a higher rate of
year-on-year decrease, from 1 January 2026, and it will wholly cease to be
payable on 31 December 2026.
· A new partnership was agreed with DSM in 2022 relating to the gut
microbiome patent, giving DSM preferential access to the use, marketing, and
sale of Fruitflow based products which are based on the patent, subject to
certain milestones which have been agreed between the parties. DSM conducted a
strong launch of the new microbiome technology
(www.dsm.com/human-nutrition/en/talking-nutrition/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html
(http://www.dsm.com/human-nutrition/en/talking-nutrition/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html)
), with widespread trade press coverage. The technology has seen strong and
ongoing interest from some significant global customers.
· Provexis will sell Fruitflow as a straight ingredient to DSM
exclusively for use in DSM's Premix Solutions and Market-Ready Solutions
businesses, with DSM then looking to sell the resulting Premix and
Market-Ready Solutions products on to its customers. The Company looks forward
to supporting DSM and its Premix and Market-Ready Solutions customers for many
years to come.
From 1 January 2023 the Group's sales channels for Fruitflow therefore
include:
1. Former DSM customers for Fruitflow;
2. DSM and its Premix and Market-Ready Solutions businesses, which will
leverage the resources and relationships of DSM in some of the major global
markets, and seek to commercialise the gut microbiome patent;
3. New customers for Fruitflow as a straight ingredient;
4. BYHEALTH and its customers, through the Company's long-term supply and
distribution agreement for Fruitflow with BYHEALTH; and
5. The Group's Fruitflow+ Omega-3 dietary supplement product which is sold
direct to consumers, the Group will also look to serve its Chinese
Cross-Border e-commerce ('CBEC') distributor for this product in China.
The Company is in discussions with a number of third parties seeking to
progress new sales and distribution opportunities for Fruitflow, and it can be
contacted for all Fruitflow sales enquiries by email at
fruitflow@provexis.com.
Fruitflow® trading for the year
In the year ended 31 March 2025 the Group's sales comprised:
Year ended Year ended
31 March 31 March
2025 2024
£ £
Fruitflow II SD ingredient 1,170,939 651,845
Fruitflow+ Omega 3 121,305 150,119
1,292,244 801,964
Sales increased by 61% year on year, primarily due to an increase of £519k
(80%) in sales of Fruitflow II SD in the year to £1.17m (2024: £652k),
reflecting strongly increased demand for Fruitflow throughout the year.
Sales of Fruitflow+ Omega 3 decreased by £29k year on year, largely due to a
CBEC order which was processed in the year ended 31 March 2024 and not
repeated in the year ended 31 March 2025.
Loss from operations for the year was £452k (2024: £604k), which included
non-cash share-based payments of £168k (2024: £121k).
Underlying operating loss for the year was £278k (2024: £469k), a decrease
of £191k year on year. The largest element of this change was a £249k
increase in gross profit, which was driven by the £490k year on year increase
in overall revenues to £1.29m (2024: £802k).
The £191k decrease in underlying operating loss also included a £24k
increase in research, patent and trade mark costs, resulting from (i) the gut
microbiome patent going into the national stage, and (ii) some additional
trade mark expenditure in a key territory.
As further outlined above a royalty is payable to DSM on the gross profits
generated from Fruitflow sales to customers transferred from DSM over the
first four years of the Transfer of Business agreement. The year ended 31
March 2025 included nine months of the royalty payable to DSM at the second
year rate to 31 December 2024, and three months of the royalty payable at the
lower third year rate to 31 March 2025. The royalty will decrease further, and
at a higher rate of year-on-year decrease, from 1 January 2026, and it will
wholly cease to be payable on 31 December 2026. Royalties payable to DSM are
included in cost of goods. The terms of the Transfer of Business agreement
otherwise remain strictly confidential between the Company and DSM.
Fruitflow II SD is currently manufactured in the EU. Rules of origin under the
post BREXIT trade deal announced in December 2020 have meant that shipments of
Fruitflow II SD from a UK fulfilment centre for re-export and sale to EU
customers are at potential risk of additional tariffs on re-entry into the EU.
Consequently, the Company setup a new Irish subsidiary company, Provexis
Ireland Limited, which started selling Fruitflow to EU customers in April 2024
via an outsourced fulfilment centre in the EU. The Company continues to use an
outsourced fulfilment centre in the UK for its non-EU customers.
Subsequent to the year end on 31 March 2025:
· All of the remaining Fruitflow II SD inventory which the Company
purchased from DSM in 2023 and 2024 has been sold, and the Company expects in
due course to report total sales for the six months ended 30 September 2025 in
excess of £350k.
· A new production run of Fruitflow II SD has been completed by the
Company's outsourced supply chain partners for Fruitflow; the Company has
received delivery of the new batch of Fruitflow II SD and is shipping the new
material out to customers.
· The Company expects to sell several hundred thousand pounds of
Fruitflow II SD in the quarter ended 31 December 2025, and is dealing with
numerous sales enquiries from existing and new customers for further direct
sales of Fruitflow in 2026 and beyond.
· In light of anticipated demand the Company is now planning with
its outsourced supply chain partners to undertake at least three further
production runs of Fruitflow II SD in the next twelve months.
BYHEALTH Co., Ltd.
In November 2021 the Company announced it had entered into a supply and
distribution agreement (the 'BYHEALTH Agreement') for Fruitflow with BYHEALTH,
a listed Chinese dietary supplement business with a market capitalisation of
approximately £2 billion.
The BYHEALTH Agreement, which followed the Company's extensive work with
BYHEALTH over the last six years, took full effect from 1 January 2023 and it
gives BYHEALTH exclusive supply and distribution rights to commercialise
Fruitflow in Mainland China, Hong Kong, Macau, Taiwan and Australia (the
'Territories').
Under the BYHEALTH Agreement Provexis is responsible for the manufacture,
supply and sale of Fruitflow to BYHEALTH, and BYHEALTH is responsible for the
manufacture, marketing and sale of Fruitflow based functional food and dietary
supplement finished products in the Territories, through BYHEALTH's extensive
sales network. BYHEALTH also has exclusive rights to act as the distributor of
Fruitflow as an ingredient in the Territories.
Provexis and BYHEALTH will seek to collaborate on research and development
projects which may result in the development and approval of Fruitflow as a
drug, for potential sale and distribution in the Territories.
The Company and BYHEALTH remain in close and constructive dialogue, at a high
level, to include joint consideration of the opportunities to file further
patents in China for Fruitflow.
Regulatory progress in China - new permitted health function claim
Provexis has been working with BYHEALTH for more than eight years to support
the planned launch of a number of Fruitflow based products in the Chinese
market. Clinical studies conducted in China are typically required to obtain
the necessary regulatory clearances in China, and a significant investment in
eight separate Fruitflow studies has been undertaken at BYHEALTH's expense.
Completed studies have shown excellent results in use for Fruitflow, and they
provide strong evidence for the efficacy of Fruitflow on platelet function.
The Chinese regulatory system for functional health food ingredients, such as
Fruitflow, is governed by the State Administration for Market Regulation (the
'SAMR') and it is based on a defined list of permitted health function claims
which brand owners are permitted to use on product labels.
The SAMR provides the possibility of adding new health function claims to the
list, with claims needing to demonstrate a relationship between a food or
nutrient and a consequent health improvement, subject to evaluation and
verification by the SAMR.
SAMR certified functional health foods are required to use a blue cap / blue
hat logo on their product packaging, which identifies products as approved
functional health foods in China.
BYHEALTH has been working on an extensive regulatory submission to the SAMR
seeking to establish a new permitted health function claim for foods such as
Fruitflow that can demonstrate an anti-platelet effect, inhibiting platelet
function and conferring beneficial health effects.
On 28 August 2023 the SAMR announced in China that the 'Implementation Rules
for Health Food New Functions and Product Technology Evaluation' (the
'Implementation Rules') had been agreed by the SAMR in June 2023, and these
new rules took effect from 28 August 2023.
On 29 August 2023 it was announced in China that BYHEALTH had submitted: i)
the first application under the Implementation Rules, seeking to obtain a new
permitted health function claim for foods such as Fruitflow which help to
'maintain normal platelet aggregation function and benefit blood flow health';
and ii) some related product registration applications.
The significance of these major developments for Fruitflow in China is further
outlined here
www.nutraingredients-asia.com/Article/2023/09/05/china-set-to-approve-new-function-claims-for-health-foods#
(http://www.nutraingredients-asia.com/Article/2023/09/05/china-set-to-approve-new-function-claims-for-health-foods)
. BYHEALTH has noted that it has been working on the project since 2015, with
'tens of millions of funds' (RMB) invested by BYHEALTH in the research and
development work.
The Company has previously stated that if BYHEALTH is successful in obtaining
a new permitted health function claim in China for functional health foods,
such as Fruitflow, that can demonstrate an anti-platelet effect, it is
expected that this would result in some significant orders for Fruitflow,
potentially at a multiple of current total sales values.
Market opportunity
The global functional food and beverage market size was US$ 364 billion in
2024 and it is projected to grow to US$ 794 billion in 2032, at a CAGR of
10.33% over the forecast period 2025-2032. Asia Pacific dominated the
functional food and beverage market with a market share of 39.45% in 2024
(source: www.fortunebusinessinsights.com/functional-foods-market-102269
(http://www.fortunebusinessinsights.com/functional-foods-market-102269) ).
Global awareness of heart health is increasing and a rising number of people
are taking a proactive approach to improving heart health. The Directors
believe that products addressing blood flow and circulation issues continue to
represent a long-term opportunity in the expanding cardiovascular sector.
Fruitflow+ dietary supplement products
Fruitflow+ Omega-3 is available to purchase from the Company's subscription
focussed e-commerce website www.fruitflowplus.com
(http://www.fruitflowplus.com) , and from Amazon UK.
The Fruitflow+ Omega-3 business reported sales in the year of £121k (2024:
£150k), reflecting largely unchanged subscriber numbers on the
www.fruitflowplus.com website, and an order from the Company's Chinese
Cross-Border e-commerce ('CBEC') channel which was processed in the year ended
31 March 2024 and not repeated in the year ended 31 March 2025.
The CBEC distribution agreement in China is separate but wholly complementary
to the Company's work with BYHEALTH, with the CBEC regulations enabling sales
of Fruitflow+ Omega-3 in China now, prior to the health function claim which
BYHEALTH is seeking to secure.
Fruitflow+ Omega-3 has a social media presence on Facebook
www.facebook.com/FruitflowPlus (http://www.facebook.com/FruitflowPlus) ,
Instagram www.instagram.com/fruitflowplus
(http://www.instagram.com/fruitflowplus) and Twitter / X
https://twitter.com/FruitflowPlus (https://twitter.com/FruitflowPlus) .
The Company is seeking to expand further its commercial activities with
Fruitflow+ Omega-3 and other Fruitflow+ combination products, and it is
currently in dialogue with some other potential international direct selling
customers.
Intellectual property
The Company is responsible for filing and maintaining patents and trade marks
for Fruitflow, and patent coverage for Fruitflow now includes the following
patent families which are all owned outright by Provexis:
Patent family Developments in the period from Sep-24 to Sep-25
Improved Fruitflow / Fruit Extracts
Improved Fruitflow / Fruit Extracts, with patents granted by the European A patent granted before the European Patent Office and validation before
Patent Office in January 2017, September 2020, April 2023 and July 2025. national patent offices is in progress.
Patents have been granted in twelve other major territories to include China
and USA; and applications are at a late stage of progression in a further
three global territories, with potential patent protection out to November
2029.
Antihypertensive (blood pressure lowering) effects
This patent was originally developed in collaboration with the University of Patent applications are pending in China and Japan.
Oslo, and it has now been granted for Fruitflow in Europe, the US and four
other territories. Patent applications are being progressed in China and
Japan, with potential patent protection out to April 2033.
In August 2020 the Company announced it had agreed to purchase the background
and joint foreground blood pressure lowering IP owned by Inven2 AS, the
technology transfer office at the University of Oslo, and Provexis now owns
these important patents outright, with the licensing option originally held by
Inven2 having been cancelled.
Fruitflow with nitrates in mitigating exercise-induced inflammation and for
promoting recovery from intense exercise
Patents have been granted around Europe and in the US, Australia, Brazil,
Canada, China, Hong Kong, India, Israel, Japan, South Korea, the Philippines, Patent applications are pending in Europe, Hong Kong and the USA.
New Zealand and Mexico.
Further patent protection is being sought in three territories, with potential
patent protection out to December 2033.
Fruitflow for air pollution
The use of Fruitflow in protecting against the adverse effects of air Patent protection has been secured in Mexico.
pollution on the body's cardiovascular system.
Laboratory work has shown that Fruitflow can reduce the platelet activation
caused by airborne particulate matter, such as that from diesel emissions, by
approximately one third.
US, Australian, Brazilian, Indonesian, Israeli, Japanese Malaysian, Mexican
and Taiwanese patents have been secured and there are pending applications in
eight jurisdictions (including the US where a further application has been
filed) which extends potential patent protection for Fruitflow out to November
2037.
Fruitflow to confer health benefits in modulating the gut microbiome of humans
The Company filed a patent application in June 2022 relating to the use of
Fruitflow to confer health benefits in modulating the gut microbiome of
humans. This followed the completion of a successful human study, the results Patent applications have been filed in Australia, Brazil, Canada, China,
of which strongly support the use of Fruitflow for modulating gut microbiota Europe, Hong Kong, India, Indonesia, Israel, Japan, South Korea, Malaysia,
to confer a number of health benefits. Mexico, New Zealand, the Philippines and the USA.
Following the completion of the international patent procedure, applications
have been filed in 16 jurisdictions (including China, Europe and the USA) with
potential patent protection out to June 2043.
Capital structure and funding
The Company is seeking to maximise the commercial returns that can be achieved
from its Fruitflow technology, and the Company's cost base and its resources
continue to be very tightly managed. The Company remains keen to minimise
dilution to shareholders and it is focussed on moving into profitability as
Fruitflow revenues increase, but while the Company remains in a loss-making
position it may need to raise funds in the future to meets its working capital
requirements.
Under the terms of the DSM Transfer of Business agreement which was announced
in June 2022, DSM's existing and prospective customers for Fruitflow II SD as
a straight ingredient (not a DSM Premix or DSM Market-Ready solution)
transferred to become direct customers of Provexis from 1 January 2023.
The Company has needed to hold Fruitflow II SD in stock from 1 January 2023
onwards to sell to new and existing customers, and it was agreed with DSM in
2022 that the Company would have the option to purchase some but not
necessarily all of DSM's remaining stocks of Fruitflow at 31 December 2022.
In the year ended 31 March 2025 the Company purchased the remainder of DSM's
2022 stocks of Fruitflow in the form of two equity settled transactions which
were completed on 5 April 2024 and 24 December 2024. Inventory with a fair
value in excess of £623,000 was acquired as part of these two share issues,
and as of 29 October 2025 the Company has sold all of the inventory which it
acquired from DSM.
In December 2024 Provexis and DSM also agreed that the estimated royalty for
the two years ended 31 December 2024 would be settled in equity, which it duly
was as part of the 24 December 2024 share issue. The Company will owe DSM
further royalties for the two years ended 31 December 2026, and the Company
will seek and has forecast in its sensitivity analysis / scenario planning to
settle these royalties in equity as well.
The share issues to DSM have been of direct benefit to the Company's cash
resources and net assets, and they have helped the Company to fund a new
production run of Fruitflow II SD which has just been completed by the
Company's outsourced supply chain partners for Fruitflow.
The Company received delivery of the new batch of Fruitflow II SD in October
2025, two months later than originally envisaged, and it has adequate funds to
pay its outsourced supply chain partners for this new inventory, in cash.
The Company is dealing with numerous sales enquiries from existing and new
customers for further direct sales of Fruitflow in 2026 and beyond, in which
favourable context the Company is now planning with its outsourced supply
chain partners to undertake at least three further production runs of
Fruitflow II SD in the next twelve months. The magnitude and timing of these
production runs will be determined with reference to (i) estimated customer
demand over the subsequent 12 to 18 months, (ii) the comparative costs and
timing of a potential production run for a new batch of material and (iii) the
Company's financial resources at that time.
The new production runs are likely to require a significant cash outlay, as
the Company is seeking by necessity to hold greater stocks of Fruitflow to
keep up with increasing demand for the product.
The Company is in ongoing dialogue with its existing and prospective customers
for Fruitflow II SD, seeking their assistance as best possible with forecast
volume estimates. A considerable degree of uncertainty is inherent in the
forecasting process, which is subject to existing and new customers' changing
plans, requirements and regulatory progress, and inevitably there is a wide
range of possible outcomes in terms of overall forecast demand.
The production process for Fruitflow II SD takes place in two stages, which
need to be booked with its outsourced supply chain partners well in advance of
production taking place. The Company is in close dialogue with all key parties
in its supply chain for Fruitflow, to include: (i) maximum capacity planning;
(ii) production cost and other efficiencies; and (iii) the potential
requirement for much larger batches of Fruitflow II SD to be made at
relatively short notice.
With regards to sensitivity analysis, management have prepared scenario
planning to stress-test potential impacts on the cash position of the
business, which have included (i) different revenue outcomes, (ii)
interruption of trade, (iii) no sales growth, (iv) customer failure, and (v)
the possible need to pay the remaining royalties due to DSM for the two years
ended 31 December 2026 in cash and not shares. In each of these downside
stress tests there are a number of mitigating actions that could be taken.
In the coming months, based on its current level of cash, the Group may
therefore need to raise further equity finance or potentially new loan
finance, subject in large part to (i) the size / volume of new production runs
of Fruitflow II SD which the Company may need to commission, with larger
production runs inevitably requiring more cash at the outset, (ii) the
different revenue outcomes which may materialise and (iii) negotiations with
DSM, which have yet to be concluded, regarding the royalty payments for the
remaining royalty bearing period to 31 December 2026, which the Company will
seek to pay in shares and not cash. These three inherently uncertain
forecasting issues are together deemed to represent a material uncertainty
related to going concern.
Considering the success of previous fundraisings and the current performance
of the business, the Directors have a reasonable expectation of raising
sufficient additional equity capital or new loan finance to continue in
operational existence for the foreseeable future. The Company is also engaged
in ongoing negotiations with a third party, potentially seeking to hold some
of its future stock requirements on a consignment basis, only paying for the
stock when it was required for sale. For these reasons the Directors continue
to adopt the going concern basis in preparing the Group's and Parent Company's
financial statements.
Annual General Meeting
The Company intends to hold its Annual General Meeting at the offices of
Allenby Capital Limited, 5th Floor, 5 St Helen's Place, London EC3A 6AB at
12:30pm on 21 November 2025.
People
The Board would like to thank the Company's small team of sales, marketing,
e-commerce, PR and scientific consultants for their professionalism,
enthusiasm and dedication in driving the business forward over the last year.
The Company would also like to thank its key professional advisers for their
valuable help and support.
Outlook
The Company is pleased to report on a year of strong progress, to include
total revenue for the year of £1.29m (2024: £802k), a 61% year on year
increase reflecting strongly increased demand from existing and new customers
for Fruitflow throughout the year.
The new long-term partnership with DSM based on the use of Fruitflow to confer
health benefits in modulating the gut microbiome of humans has continued to
progress well. The technology was launched by DSM in January 2023 with
widespread trade press coverage, and it has seen strong and ongoing interest
from some significant global customers.
Provexis has been working with BYHEALTH for more than eight years to support
the planned launch of a number of Fruitflow based products in the Chinese
market. In August 2023 the Company was delighted to report that BYHEALTH had
submitted: i) the first application for a new permitted health function claim
and ii) some related product registration applications. BYHEALTH has noted
that it has been working on the project since 2015, with 'tens of millions of
funds' (RMB) invested by BYHEALTH in the research and development work.
The Company has developed a strong, long lasting and wide-ranging patent
portfolio for Fruitflow, and it owns outright four existing patent families
for Fruitflow. The new microbiome patent application takes this to a potential
total of five patent families, with potential patent protection now running
out to 2042. The four existing patent families have a truly global footprint,
and the Company also holds other valuable intellectual property and trade
secrets for Fruitflow. The intellectual property for Fruitflow is of
fundamental importance to the Company and its current and future commercial
partners, to include DSM and BYHEALTH, and it underpins the numerous
commercial opportunities which the Company and its partners are pursuing for
Fruitflow.
Subsequent to the year end on 31 March 2025 all of the remaining Fruitflow
inventory which the Company purchased from DSM has been sold, and the Company
expects in due course to report total sales for the six months ended 30
September 2025 in excess of £350k. A new production run of Fruitflow II SD
has just been completed and the Company is now shipping the new material out
to customers. The Company expects to sell several hundred thousand pounds of
Fruitflow II SD in the quarter ended 31 December 2025, and is dealing with
numerous sales enquiries from existing and new customers for further direct
sales of Fruitflow in 2026 and beyond, in light of which the Company is
planning to undertake at least three further production runs of Fruitflow II
SD in the next twelve months.
The Company expects that (i) the significant changes to the sales and supply
chain structure for Fruitflow from January 2023 and the new Provexis Ireland
operation, (ii) the gut microbiome patent application and related long-term
partnership with DSM and (iii) the recent BYHEALTH regulatory developments in
China will have a strongly beneficial effect on the current and future
commercial prospects for Fruitflow and the business worldwide. The Company
would like to thank its customers and shareholders for their continued
support, and the Board remains strongly positive about the outlook for
Fruitflow and the Provexis business for the coming year and beyond.
Dawson Buck Ian Ford
Chairman CEO
Strategic report
Group strategy
The Group strategy has historically focused on the discovery, development and
commercialisation of functional foods, medical foods and dietary supplements,
and in particular the Group's Fruitflow technology.
Provexis entered into a long-term Alliance Agreement with DSM Nutritional
Products ('DSM') in 2010 to commercialise Fruitflow through sales as an
ingredient to brand owners in the food, beverage and dietary supplement
categories. More than 100 regional consumer healthcare brands have now been
launched by direct customers of DSM, and a number of further regional brands
have been launched through DSM's distributor channels.
In June 2022 Provexis announced it had secured two new agreements with DSM for
Fruitflow, to replace the Alliance Agreement: (i) a Transfer of Business
agreement and (ii) a Premix and Market-Ready Solutions supply agreement, which
both took effect on 1 January 2023. DSM's existing and prospective customers
for Fruitflow as a straight ingredient transferred to become direct customers
of Provexis from 1 January 2023, and Provexis took over the outsourced supply
chain / production process for Fruitflow at that time.
Fruitflow has a number of specific health benefits which have been reflected
in separate patent filings for the use of Fruitflow in:
· mitigating exercise-induced inflammation;
· managing blood pressure;
· protecting against the adverse effects of air pollution on the
body's cardiovascular system. Laboratory work has shown that Fruitflow can
reduce the platelet activation caused by airborne particulate matter, such as
that from diesel emissions, by approximately one third; and
· conferring health benefits in modulating the gut microbiome of
humans, to include a reduction in TMAO, following the completion of a
successful human study which is further detailed here
www.dsm.com/human-nutrition/en/talking-nutrition/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html
(http://www.dsm.com/human-nutrition/en/talking-nutrition/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html)
.
A new partnership was agreed with DSM in June 2022 relating to the
commercialisation of the gut microbiome patent, subject to certain milestones
which have been agreed between the parties.
In November 2021 Provexis entered into a long-term supply and distribution
agreement for Fruitflow with BYHEALTH Co., Ltd. ('BYHEALTH'), a £2bn listed
Chinese dietary supplement business, to support the planned launch of some
Fruitflow based products in the Chinese market. The planned launch is
progressing well with potential sales volumes remaining at a significant
multiple of existing Fruitflow sales.
BYHEALTH has been working on an extensive regulatory submission to the Chinese
State Administration for Market Regulation (the 'SAMR') seeking to establish a
new permitted health function claim for foods such as Fruitflow that can
demonstrate an anti-platelet effect.
In August 2023 the SAMR announced in China that the 'Implementation Rules for
Health Food New Functions and Product Technology Evaluation' had been agreed
by the SAMR in June 2023, and on 29 August 2023 BYHEALTH submitted: i) the
first application under the Implementation Rules, seeking to obtain a new
permitted health function claim for foods such as Fruitflow which help to
'maintain normal platelet aggregation function and benefit blood flow health';
and ii) some related product registration applications.
BYHEALTH has noted that it has been working on the project since 2015, with
'tens of millions of funds' (RMB) invested by BYHEALTH in the research and
development work.
It has been a key strategic priority for the Group to develop a strong, long
lasting and wide-ranging patent portfolio for Fruitflow, and it owns outright
four existing patent families for Fruitflow. The new microbiome patent
application takes this to a potential total of five patent families, with
potential patent protection now running out to 2042. The four existing patent
families have a truly global footprint, and the Company also holds other
valuable intellectual property and trade secrets for Fruitflow. The
intellectual property for Fruitflow is of fundamental importance to the
Company and its current and future commercial partners, to include DSM and
BYHEALTH, and it underpins the numerous commercial opportunities which the
Company and its partners are pursuing for Fruitflow.
Market opportunity
Fruitflow is a patented natural extract from tomatoes which has been shown in
human trials to reduce the propensity for aberrant blood clotting, typically
associated with cardiovascular disease, which can lead to heart attack and
stroke. The extract is available as a spray-dried powder and it can be
included in a broad range of food, beverage and dietary supplement formats.
In May 2009, the Company's Fruitflow technology was the first to be
substantiated by the European Food Safety Authority ('EFSA') under the new
Article 13(5) for proprietary and emerging science. In December 2009 the
European Commission authorised the health claim 'Helps maintain normal
platelet aggregation, which contributes to healthy blood flow', which was the
first wording to be authorised under Article 13(5).
The global functional food and beverage market size was US$ 364 billion in
2024 and it is projected to grow to US$ 794 billion in 2032, at a CAGR of
10.33% over the forecast period 2025-2032. Asia Pacific dominated the
functional food and beverage market with a market share of 39.45% in 2024
(source: www.fortunebusinessinsights.com/functional-foods-market-102269
(http://www.fortunebusinessinsights.com/functional-foods-market-102269) ).
Global awareness of heart health is increasing and a rising number of people
are taking a proactive approach to improving heart health. The Directors
believe that products addressing blood flow and circulation issues continue to
represent a long-term opportunity in the expanding cardiovascular sector.
Financial review
The financial review has been prepared on the basis of Group's continuing
operations, as further detailed in the consolidated statement of comprehensive
income.
Revenue
In June 2022 the Company announced that it had entered into two new agreements
with DSM for Fruitflow, to replace the Alliance Agreement for the period after
31 December 2022, being: (i) a Transfer of Business agreement for Fruitflow
and (ii) a Premix and Market-Ready Solutions supply agreement for Fruitflow,
which both took effect from 1 January 2023.
In the year ended 31 March 2025 the Group's sales comprised:
Year ended Year ended
31 March 31 March
2025 2024
£ £
Fruitflow II SD ingredient 1,170,939 651,845
Fruitflow+ Omega 3 121,305 150,119
1,292,244 801,964
Sales increased by 61% year on year, primarily due to an increase of £519k
(80%) in sales of Fruitflow II SD in the year to £1.17m (2024: £652k),
reflecting strongly increased demand for Fruitflow throughout the year.
Sales of Fruitflow+ Omega 3 decreased by £29k year on year, largely due to a
CBEC order which was processed in the year ended 31 March 2024 and not
repeated in the year ended 31 March 2025.
From 1 January 2023, the principal sales channels for the Group's Fruitflow II
SD ingredient are:
1. Former DSM customers for Fruitflow;
2. DSM and its Premix and Market-Ready Solutions businesses, which will
leverage the resources and relationships of DSM in some of the major global
markets, and seek to commercialise the gut microbiome patent;
3. New customers for Fruitflow as a straight ingredient; and
4. BYHEALTH and its customers, through the Company's long-term supply and
distribution agreement for Fruitflow with BYHEALTH.
The Group's Fruitflow+ Omega-3 dietary supplement product is sold to:
1. Direct consumers, via the Company's website www.fruitflowplus.com
(http://www.fruitflowplus.com) which is particularly focussed on subscription
orders;
2. The Group's Chinese Cross-Border e-commerce distributor for Fruitflow+
Omega-3 in China; and
3. Consumers via Amazon UK.
Fruitflow+ Omega-3 has a Facebook page at www.facebook.com/FruitflowPlus
(http://www.facebook.com/FruitflowPlus) and an Instagram page at
www.instagram.com/fruitflowplus (http://www.instagram.com/fruitflowplus) .
Further sales channel opportunities for the product continue to be explored.
Underlying operating loss
Underlying operating loss for the year was £278k (2024: £469k), a decrease
of £191k year on year. The largest element of this change was a £249k
increase in gross profit, which was driven by the £490k year on year increase
in overall revenues to £1.29m (2024: £802k).
The £191k decrease in underlying operating loss also included a £24k
increase in research, patent and trade mark costs, resulting from (i) the gut
microbiome patent going into the national stage, and (ii) some additional
trade mark expenditure in a key territory.
It should also be noted, as previously confirmed by the Company:
1. A royalty is payable to DSM on the gross profits generated from
Fruitflow sales to customers transferred from DSM over the first four years of
the Transfer of Business agreement. From 1 January 2023 the net profit
accruing to Provexis on sales of Fruitflow in the calendar year - on a
pro-forma basis, assuming like for like sales and margins - would be
materially ahead of the net share of the profit that would have accrued to
Provexis with like for like sales and margins under the existing 2010 Alliance
Agreement; on the same pro-forma basis, assuming like for like sales and
margins, the net profit accruing to Provexis would further increase in each of
the subsequent three calendar years. The year ended 31 March 2025 therefore
included nine months of the royalty at the second year rate to 31 December
2024, and three months of the royalty at the lower third year rate. Royalties
payable to DSM are included in cost of goods. The terms of the Transfer of
Business agreement otherwise remain strictly confidential between the Company
and DSM.
2. Fruitflow II SD is currently manufactured in the EU. Rules of origin
under the BREXIT trade deal announced in December 2020 have meant that
shipments of Fruitflow II SD from a UK fulfilment centre for re-export and
sale to EU customers are at potential risk of additional tariffs on re-entry
into the EU (see www.bbc.co.uk/news/55648201
(http://www.bbc.co.uk/news/55648201) ). Consequently, the Company setup a new
Irish subsidiary company, Provexis Ireland Limited, which started selling
Fruitflow to EU customers in April 2024 via an outsourced fulfilment centre in
the EU. The Company continues to use an outsourced fulfilment centre in the UK
for its non-EU customers.
A reconciliation of the underlying operating loss to statutory operating loss
is provided below:
Year ended Year ended
31 March 31 March
2025 2024
£ £
Revenue 1,292,244 801,964
Cost of goods (759,304) (518,169)
Gross profit 532,940 283,795
Selling and distribution costs (68,338) (65,706)
Research, patent and trade mark costs (325,625) (301,722)
Administrative costs - share-based payment charges (168,317) (121,051)
Administrative costs - other (422,631) (398,908)
Loss from operations (451,971) (603,592)
Adjust loss from operations for:
Administrative costs - share-based payment charges 168,317 121,051
Taxation - R&D tax relief: receivable tax credit 5,502 13,880
Underlying operating loss for the year (278,152) (468,661)
The Group has chosen to report underlying operating loss as the Directors
believe that the operating loss before share-based payments, and including
R&D tax relief, provides additional useful information for shareholders on
underlying trends and performance. This measure is used for internal
performance analysis. The Group's cost base and its resources have been and
will continue to be tightly managed within budgets approved and monitored by
the Board.
Research, patent and trade mark costs
Research, patent and trade mark costs are primarily composed of patent, trade
mark and other research agreement costs, with the Group seeking to maintain
and strengthen the breadth and duration of its patent and trade mark coverage
for Fruitflow. Research, patent and trade mark costs have increased by 8% to
£326k (2024: £302k) resulting from (i) the gut microbiome patent going into
the national stage, and (ii) some additional trade mark expenditure in a key
territory.
Taxation
The current tax charge of £9k (2024: £Nil) relates to Corporation Tax for
Provexis Ireland at the 12.5% rate for Irish trading income.
A current tax credit of £6k (2024: £14k), in respect of research and
development tax relief has been recognised in the financial statements, £Nil
of which (2024: £Nil) relates to prior years.
No amounts in respect of deferred tax were recognised in profit and loss from
continuing operations or charged / credited to equity for the current or prior
year.
Results and dividends
The loss attributable to equity holders of the parent for the year ended 31
March 2025 was £453k (2024: £586k) and the basic and fully diluted loss per
share was 0.02p (2024: 0.03p). The Directors are unable to recommend the
payment of a dividend (2024: £Nil).
Consideration of section 656 of the Companies Act 2006
On 28 August 2014 it was noted in the Company's Notice of Annual General
Meeting that Section 656 of the Companies Act 2006 ('section 656') had been
brought to the attention of the Directors as part of the 31 March 2014 year
end accounts and audit. Section 656 states that where the net assets of a
public company are half or less of its called-up share capital, the Directors
must call a general meeting of the company to consider whether any, and if so
what, steps should be taken to deal with the situation.
Further details of the issue were provided in the Company's AGM notice of 28
August 2014 which is available to download from the Company's website here
www.provexis.org/wp-content/uploads/Provexis-plc-notice-of-22-Sep-14-AGM-FINAL.pdf
(http://www.provexis.org/wp-content/uploads/Provexis-plc-notice-of-22-Sep-14-AGM-FINAL.pdf)
A resolution was not put to the 2014 Annual General Meeting in connection with
section 656 and it was noted that the Directors' view in August 2014 was that
the most appropriate course of action was to continue to maintain tight
control over the running costs of the Company and to wait for revenues from
its core Fruitflow product to increase. Subsequent to the Company's AGM on 22
September 2014 the net assets of the Company and Group have remained less than
half of the Company's called-up share capital and a further general meeting of
the Company is not required under section 656.
The annual financial statements of the Company for the year ended 31 March
2025 and the reports of the Directors thereon include a going concern
statement which concludes that the necessity to raise additional equity or
loan finance represents a material uncertainty that may cast significant doubt
upon the Group's and Parent Company's ability to continue as a going concern
and that should it be unable to raise further funds, the Group may be unable
to realise its assets and discharge its liabilities in the normal course of
business.
Considering the success of previous fundraisings and the current performance
of the business, the Directors have a reasonable expectation of raising
sufficient additional equity capital or new loan finance to continue in
operational existence for the foreseeable future. Subject to the outcome of
ongoing negotiations with a third party, the Company might also be able to
hold some of its future stock requirements on a consignment basis, only paying
for the stock when it was required for sale. For these reasons the Directors
continue to adopt the going concern basis in preparing the Group's and Parent
Company's financial statements.
It remains the Directors' view on 29 October 2025 that the most appropriate
course of action in respect of section 656 is to continue to seek to maximise
the commercial returns that can be achieved from the Company's Fruitflow
technology, and continue to maintain very tight control over the running costs
of the Company.
Capital structure and funding
The Company is seeking to maximise the commercial returns that can be achieved
from its Fruitflow technology, and the Company's cost base and its resources
continue to be very tightly managed. The Company remains keen to minimise
dilution to shareholders and it is focussed on moving into profitability as
Fruitflow revenues increase, but while the Company remains in a loss-making
position it may need to raise funds in the future to meets its working capital
requirements.
Under the terms of the DSM Transfer of Business agreement which was announced
in June 2022, DSM's existing and prospective customers for Fruitflow II SD as
a straight ingredient (not a DSM Premix or DSM Market-Ready solution)
transferred to become direct customers of Provexis from 1 January 2023.
The Company has needed to hold Fruitflow II SD in stock from 1 January 2023
onwards to sell to new and existing customers, and it was agreed with DSM in
2022 that the Company would have the option to purchase some but not
necessarily all of DSM's remaining stocks of Fruitflow at 31 December 2022.
In the year ended 31 March 2025 the Company purchased the remainder of DSM's
2022 stocks of Fruitflow in the form of two equity settled transactions which
were completed on 5 April 2024 and 24 December 2024. Inventory with a fair
value in excess of £623,000 was acquired as part of these two share issues,
and as of 29 October 2025 the Company has sold all of the inventory which it
acquired from DSM.
In December 2024 Provexis and DSM also agreed that the estimated royalty for
the two years ended 31 December 2024 would be settled in equity, which it duly
was as part of the 24 December 2024 share issue. The Company will owe DSM
further royalties for the two years ended 31 December 2026, and the Company
will seek and has forecast in its sensitivity analysis / scenario planning to
settle these royalties in equity as well.
The share issues to DSM have been of direct benefit to the Company's cash
resources and net assets, and they have helped the Company to fund a new
production run of Fruitflow II SD which has just been completed by the
Company's outsourced supply chain partners for Fruitflow.
The Company received delivery of the new batch of Fruitflow II SD in October
2025, two months later than originally envisaged, and it has adequate funds to
pay its outsourced supply chain partners for this new inventory, in cash.
The Company is dealing with numerous sales enquiries from existing and new
customers for further direct sales of Fruitflow in 2026 and beyond, in which
favourable context the Company is now planning with its outsourced supply
chain partners to undertake at least three further production runs of
Fruitflow II SD in the next twelve months. The magnitude and timing of these
production runs will be determined with reference to (i) estimated customer
demand over the subsequent 12 to 18 months, (ii) the comparative costs and
timing of a potential production run for a new batch of material and (iii) the
Company's financial resources at that time.
The new production runs are likely to require a significant cash outlay, as
the Company is seeking by necessity to hold greater stocks of Fruitflow to
keep up with increasing demand for the product.
The Company is in ongoing dialogue with its existing and prospective customers
for Fruitflow II SD, seeking their assistance as best possible with forecast
volume estimates. A considerable degree of uncertainty is inherent in the
forecasting process, which is subject to existing and new customers' changing
plans, requirements and regulatory progress, and inevitably there is a wide
range of possible outcomes in terms of overall forecast demand.
The production process for Fruitflow II SD takes place in two stages, which
need to be booked with its outsourced supply chain partners well in advance of
production taking place. The Company is in close dialogue with all key parties
in its supply chain for Fruitflow, to include: (i) maximum capacity planning;
(ii) production cost and other efficiencies; and (iii) the potential
requirement for much larger batches of Fruitflow II SD to be made at
relatively short notice.
With regards to sensitivity analysis, management have prepared scenario
planning to stress-test potential impacts on the cash position of the
business, which have included (i) different revenue outcomes, (ii)
interruption of trade, (iii) no sales growth, (iv) customer failure, and (v)
the possible need to pay the remaining royalties due to DSM for the two years
ended 31 December 2026 in cash and not shares. In each of these downside
stress tests there are a number of mitigating actions that could be taken.
In the coming months, based on its current level of cash, the Group may
therefore need to raise further equity finance or potentially new loan
finance, subject in large part to (i) the size / volume of new production runs
of Fruitflow II SD which the Company may need to commission, with larger
production runs inevitably requiring more cash at the outset, (ii) the
different revenue outcomes which may materialise and (iii) negotiations with
DSM, which have yet to be concluded, regarding the royalty payments for the
remaining royalty bearing period to 31 December 2026, which the Company will
seek to pay in shares and not cash. These three inherently uncertain
forecasting issues are together deemed to represent a material uncertainty
related to going concern.
Considering the success of previous fundraisings and the current performance
of the business, the Directors have a reasonable expectation of raising
sufficient additional equity capital or new loan finance to continue in
operational existence for the foreseeable future. The Company is also engaged
in ongoing negotiations with a third party, potentially seeking to hold some
of its future stock requirements on a consignment basis, only paying for the
stock when it was required for sale. For these reasons the Directors continue
to adopt the going concern basis in preparing the Group's and Parent Company's
financial statements.
Key performance indicators
The principal financial KPIs monitored by the Board relate to underlying
operating loss and cash and cash equivalents.
The table below shows the Group's underlying operating loss, calculated as
loss from operations adjusted for share-based payment charges and R&D tax
relief, for the two years ended 31 March 2025:
Year ended Year ended
31 March 31 March
2025 2024
£ £
Loss from operations 451,971 603,592
Adjust loss from operations for:
Administrative costs - share-based payment charges (168,317) (121,051)
Taxation - R&D tax relief: receivable tax credit (5,502) (13,880)
Underlying operating loss 278,152 468,661
The trading results are further detailed in this strategic report.
The table below shows the Group's cash position at 31 March 2025 and 31 March
2024:
31 March 31 March
2025 2024
£ £
Cash and cash equivalents 708,087 189,357
The monitoring of cash gives due consideration to anticipated future spend
required to prioritise development opportunities and to plan the resources
required to achieve the goals of the business. The £518,730 increase in cash
and cash equivalents during the financial year is further detailed in the
consolidated statement of cash flows.
Principal risks and uncertainties
In the course of its normal business the Group is exposed to a range of risks
and uncertainties which could impact on the results of the Group.
The Board considers that risk-management is an integral part of good business
process and, it maintains a register of risks across several categories
including consultants, clients, competition, finance, technical and legal. For
each risk the Board estimates the impact, likelihood as well as identify
mitigating strategies.
This register is reviewed periodically as the Company's situation changes.
During such reviews, each risk category is considered by the Directors with a
view to understanding (i) whether the nature, impact or likelihood of any
risks has changed, (ii) whether the mitigating actions taken by the Company
should change as a result and (iii) whether any new risks or categories of
risk have arisen since the last review.
Provexis entered into a long-term Alliance Agreement with DSM Nutritional
Products in 2010 to commercialise Fruitflow through sales as an ingredient to
brand owners in the food, beverage and dietary supplement categories, and in
June 2022 Provexis announced it had secured two new agreements with DSM for
Fruitflow, to replace the Alliance Agreement: (i) a Transfer of Business
agreement and (ii) a Premix and Market-Ready Solutions supply agreement, which
both took effect on 1 January 2023. DSM's existing and prospective customers
for Fruitflow as a straight ingredient transferred to become direct customers
of Provexis from 1 January 2023, and Provexis took over the outsourced supply
chain / production process for Fruitflow at that time.
Under these new agreements the Company is seeking to expand its Fruitflow
direct selling business and thereby reduce its past commercial reliance on the
Alliance Agreement with DSM, as further outlined above. For some time the
Company has been seeking to expand its Fruitflow+ Omega-3 dietary supplement
business. The Company is therefore seeking to increase its opportunities for
growth and decrease the risk inherent in its past commercial reliance on the
Alliance Agreement with DSM.
The Directors have identified the following principal risks and uncertainties
that could have the most significant impact on the Group's long-term value
generation.
Funding and other risks
Provexis has experienced operating losses from continuing operations in each
year since its inception. Accordingly until Provexis has sufficient commercial
success with Fruitflow to be cash generative it will continue to rely on its
existing cash resources and further funding rounds to continue its activities.
While Provexis aims to generate licensing and sales revenues from Fruitflow,
there is no certainty that such revenues will be generated. Furthermore, the
amount and timing of revenues from Fruitflow is uncertain and will depend on
numerous factors, most of which have in the past been outside Provexis'
control due to the terms of the Alliance Agreement. It is therefore difficult
for the Directors to predict with accuracy the timing and amount of any
further capital that may be required by the Provexis Group.
Factors that could increase Provexis' funding requirements include, but are
not limited to: higher operational costs; slower progress than expected in
attracting customers to purchase Fruitflow; unexpected opportunities to
develop additional products or acquire additional technologies, products or
businesses; costs incurred in relation to the protection of Provexis'
intellectual property, and the additional working capital (in particular:
inventory) which Provexis is now required to hold as a result of the June 2022
(i) Transfer of Business agreement for Fruitflow with DSM and (ii) Premix and
Market-Ready Solutions supply agreement for Fruitflow with DSM, which both
took effect from 1 January 2023.
Any additional share issues may have a dilutive effect on Provexis
Shareholders. Further, there can be no guarantee or assurance that additional
equity funding will be forthcoming when required, nor as to the terms and
price on which such funds would be available, nor that such funds, if raised,
would be sufficient to enable Provexis to meet its working capital
requirements.
Commercialisation
Between 2010 and 2022, due to the terms of the Alliance Agreement, Provexis
was largely dependent on DSM in respect of the development, production,
marketing and commercialisation of Fruitflow, and Provexis' long-term success
has been largely dependent on the ability of DSM to sell Fruitflow.
It has been noted in prior years that Provexis' negotiating position with DSM
could have been affected by its size and limited cash resources relative to
DSM which has substantial cash resources and established levels of commercial
success. An inability to enter into any discussions with DSM on equal terms
could have led to reduced revenue from the Alliance Agreement which may have
had a significant adverse effect on Provexis' business, financial condition
and results.
In June 2022 the Company announced that the Company and DSM had concluded
their negotiations to replace the Alliance Agreement and had entered into (i)
a Transfer of Business agreement for Fruitflow and (ii) a Premix and
Market-Ready Solutions supply agreement for Fruitflow, which both took effect
from 1 January 2023.
Under these new agreements the Company is seeking to expand its Fruitflow
direct selling business and thereby reduce its past commercial reliance on the
Alliance Agreement with DSM, as further outlined above. For some time the
Company has been seeking to expand its Fruitflow+ Omega-3 dietary supplement
business. The Company is therefore seeking to increase its opportunities for
growth and decrease the risk inherent in its past commercial reliance on the
Alliance Agreement with DSM.
The success of Provexis will depend on the market's acceptance and valuing of
Fruitflow and there can be no guarantee that this acceptance will be
forthcoming or that Provexis' technologies will succeed. The development of a
market for Fruitflow will be affected by many factors, some of which are
beyond Provexis' control, including the emergence of newer, more successful
food IP and products and the cost of Fruitflow. Notwithstanding the health
claims made in respect of Fruitflow, there can be no guarantee that Provexis'
targeted customer base for the product will purchase or continue to purchase
the product. If a market fails to develop or develops more slowly than
anticipated, Provexis may be unable to recover the losses it may have incurred
in the development of Fruitflow and may never achieve profitability.
Limited product offering
Provexis has only one product, Fruitflow, and any problems with the commercial
success of Fruitflow will impact the financial performance of Provexis.
Intellectual property protection
Provexis is heavily dependent on its intellectual property and, in particular,
its patents. No assurance can be given that any pending patent applications or
any future patent applications will result in granted patents, that any
patents will be granted on a timely basis, that the scope of any copyright or
patent protection will exclude competitors or provide competitive advantages
to Provexis, that any of Provexis' patents will be held valid if challenged,
or that third parties will not claim rights in or ownership of the copyright,
patents and other proprietary rights held by Provexis.
Further, there can be no assurance that others have not developed or will not
develop similar products, duplicate any of Provexis' products or design around
any patents held by Provexis. Others may hold or receive patents which contain
claims having a scope that covers products developed by Provexis (whether or
not patents are issued to Provexis).
Provexis may rely on patents to protect its assets. These rights act only to
prevent a competitor exploiting the technology defined by granted patent
claims and not to prevent a competitor from independently developing different
products that perform the same functions. No assurance can be given that
others will not independently develop or otherwise acquire substantially
equivalent functional food IP or otherwise gain access to Provexis' unpatented
proprietary technology or disclose such technology or that Provexis can
ultimately protect meaningful rights to such unpatented technology.
Once granted, a patent can be challenged both in the patent office and in the
courts by third parties. Third parties can bring material and arguments which
the patent office granting the patent may not have seen. Therefore, issued
patents may be found by a court of law or by the patent office to be invalid
or unenforceable or in need of further restriction.
A substantial cost may be incurred if Provexis is required to assert its
intellectual property rights, including any patents or trade marks against
third parties. Litigation is costly and time consuming and there can be no
assurance that Provexis will have, or will be able to devote, sufficient
resources to pursue such litigation. Potentially unfavourable outcomes in such
proceedings could limit Provexis' intellectual property rights and activities.
There is no assurance that obligations to maintain Provexis' know how would
not be breached or otherwise become known in a manner which provides Provexis
with no recourse.
Any claims made against Provexis' intellectual property rights, even without
merit, could be time consuming and expensive to defend and could have a
materially detrimental effect on Provexis' resources. A third party asserting
infringement claims against Provexis could require Provexis to cease the
infringing activity and/or require Provexis to enter into licensing and
royalty arrangements. The third party could also take legal action which could
be costly. In addition, Provexis may be required to develop alternative
non-infringing solutions that may require significant time and substantial
unanticipated resources. There can be no assurance that such claims will not
have a material adverse effect on Provexis' business, financial condition or
results.
Future development
The future development of the Company is discussed in the Chairman and CEO's
statement.
Ian Ford
Director
Consolidated statement of comprehensive income
Year Year
ended ended
31 March 31 March
2025 2024
Notes £ £
Revenue 1,3 1,292,244 801,964
Cost of goods sold (759,304) (518,169)
Gross profit 532,940 283,795
Selling and distribution costs (68,338) (65,706)
Research, patent and trade mark costs 4 (325,625) (301,722)
Administrative costs - share-based payment charges 4,16 (168,317) (121,051)
Administrative costs - other (422,631) (398,908)
Loss from operations 4 (451,971) (603,592)
Finance income 7 2,334 1,594
Loss before taxation (449,637) (601,998)
Taxation 8 (3,083) 13,880
Loss and total comprehensive loss for the year (452,720) (588,118)
Attributable to:
Owners of the parent (452,720) (586,243)
Non-controlling interest - (1,875)
Loss and total comprehensive loss for the year (452,720) (588,118)
Loss per share to owners of the parent
Basic - pence 9 (0.02) (0.03)
Diluted - pence 9 (0.02) (0.03)
Consolidated statement of financial position
Company number 05102907 As at As at
31 March 31 March
2025 2024
Notes £ £
Assets
Current assets
Inventories 11 202,352 136,520
Trade and other receivables 12 82,202 125,479
Corporation tax asset 8 19,380 46,680
Cash and cash equivalents 708,087 189,357
Total current assets 1,012,021 498,036
Total assets 1,012,021 498,036
Liabilities
Current liabilities
Trade and other payables 13 (239,621) (307,448)
Current tax liabilities 8 (8,585) -
Total current liabilities (248,206) (307,448)
Total liabilities (248,206) (307,448)
Total net assets 763,815 190,588
Capital and reserves attributable to
owners of the Parent company
Share capital 15 2,345,891 2,217,822
Share premium 17 19,432,882 18,703,321
Merger reserve 17 6,599,174 6,599,174
Retained earnings 17 (27,080,383) (26,795,980)
1,297,564 724,337
Non-controlling interest (533,749) (533,749)
Total equity 763,815 190,588
Consolidated statement of cash flows
Year Year
ended ended
31 March 31 March
2025 2024
Notes
£ £
Cash flows from operating activities
Loss after tax (452,720) (588,118)
Adjustments for:
Finance income 7 (2,334) (1,594)
Taxation 8 3,083 (13,880)
Share-based payment charges - share options 16 168,317 121,051
Changes in inventories (65,832) 191,277
Changes in trade and other receivables 43,682 (64,505)
Changes in trade and other payables (67,827) 119,111
Net cash flow from operations (373,631) (236,658)
Tax credits received 32,802 45,160
Total cash flow from operating activities (340,829) (191,498)
Cash flow from investing activities
Interest received 1,929 1,734
Total cash flow from investing activities 1,929 1,734
Cash flow from financing activities
Proceeds from issue of share capital 15 857,630 -
Total cash flow from financing activities 857,630 -
Net change in cash and cash equivalents 518,730 (189,764)
Opening cash and cash equivalents 189,357 379,121
Closing cash and cash equivalents 708,087 189,357
Consolidated statement of changes in equity
Share Share Merger Retained Total equity Non-controlling Total
capital premium reserve earnings attributable to owners of interests equity
the parent
£ £ £ £ £ £ £
At 31 March 2023 2,217,822 18,703,321 6,599,174 (26,330,788) 1,189,529 (531,874) 657,655
Share-based charges - share options - - - 121,051 121,051 - 121,051
Total comprehensive loss for the year - - - (586,243) (586,243) (1,875) (588,118)
At 31 March 2024 2,217,822 18,703,321 6,599,174 (26,795,980) 724,337 (533,749) 190,588
Share-based charges - share - - - 168,317 168,317 - 168,317
options and warrants
Issue of shares - 5 April 2024 45,123 249,036 - - 294,159 - 294,159
Issue of shares - 24 December 2024 82,946 480,525 - - 563,471 - 563,471
Total comprehensive loss for the year - - - (452,720) (452,720) - (452,720)
At 31 March 2025 2,345,891 19,432,882 6,599,174 (27,080,383) 1,297,564 (533,749) 763,815
Notes to the preliminary results for the year ended 31 March 2025
1. Accounting policies
General information
Provexis plc is a public limited company incorporated and domiciled in the
United Kingdom (registration number 05102907). The address of the registered
office is 2 Blagrave Street, Reading, Berkshire RG1 1AZ, UK. The functional
and presentational currency is pounds sterling and the financial statements
are rounded to the nearest £1.
The main activities of the Group are those of developing, licensing and
selling the proprietary, scientifically-proven Fruitflow heart-health
functional food ingredient for the global functional food sector.
Basis of preparation
The financial information set out in this release does not constitute the
Company's full statutory accounts for the year ended 31 March 2025 for the
purposes of section 434(3) of the Companies Act 2006, but it is derived from
those accounts that have been audited. Statutory accounts for 2024 have been
delivered to the Registrar of Companies and those for 2025 will be delivered
on 30 October 2025. The auditors have reported on the accounts for the year
ended 31 March 2025; and whilst their audit report was not modified their
report does contain a material uncertainty related to going concern, as set
out in the going concern paragraph of this announcement.
While the financial information included in this preliminary announcement has
been prepared in accordance with the recognition and measurement principles of
International Financial Reporting Standards (IFRS) as endorsed for use in the
United Kingdom, this announcement does not itself contain sufficient
information to comply with IFRS. The Company expects to publish full financial
statements for the year ended 31 March 2025 that comply with IFRS on 30
October 2025.
The accounting policies set out below have been applied to all periods
presented in these Group financial statements and are in accordance with
UK-adopted International accounting standards ('IFRS'), and International
Financial Reporting Interpretations Committee ('IFRIC') interpretations that
were applicable for the year ended 31 March 2025.
These accounting policies are consistent with those applied in the year ended
31 March 2024, as amended to reflect any new Standards, amendments to
Standards and interpretations which are mandatory for the year ended 31 March
2025. The adoption of these revised standards and interpretations has not had
an impact on the current and comparative figures recorded.
The IASB has issued a number of standards and interpretations with an
effective date after the date of these financial statements, none of which are
expected to have a material impact on the Group's reported financial
performance or position.
Going concern
The Group's business activities together with the factors likely to affect its
future development, and the financial position of the Group, its cash flows
and liquidity position are set out in the strategic report. In addition note 2
to the financial statements includes the Group's objectives, policies and
processes for managing its capital; its financial risk management objectives;
details of its financial instruments and its exposure to credit and liquidity
risk.
The Group made a loss for the year of £452,720 (2024: £588,118), which
includes non-cash share-based payment charges of £168,317 (2024: £121,051)
and expects to make a further loss during the year ending 31 March 2026. The
total cash outflow from operations in the year was £340,829 (2024:
£191,498). At 31 March 2025 the Group had cash balances of £708,087 (2024:
£189,357).
The directors have prepared projected cash flow information for a period of
more than twelve months from the date of approval of these financial
statements and have reviewed this information as at the date of these
financial statements.
The Company is seeking to maximise the commercial returns that can be achieved
from its Fruitflow technology, and the Company's cost base and its resources
continue to be very tightly managed. The Company remains keen to minimise
dilution to shareholders and it is focussed on moving into profitability as
Fruitflow revenues increase, but while the Company remains in a loss-making
position it may need to raise funds in the future to meets its working capital
requirements.
Under the terms of the DSM Transfer of Business agreement which was announced
in June 2022, DSM's existing and prospective customers for Fruitflow II SD as
a straight ingredient (not a DSM Premix or DSM Market-Ready solution)
transferred to become direct customers of Provexis from 1 January 2023.
The Company has needed to hold Fruitflow II SD in stock from 1 January 2023
onwards to sell to new and existing customers, and it was agreed with DSM in
2022 that the Company would have the option to purchase some but not
necessarily all of DSM's remaining stocks of Fruitflow at 31 December 2022.
In the year ended 31 March 2025 the Company purchased the remainder of DSM's
2022 stocks of Fruitflow in the form of two equity settled transactions which
were completed on 5 April 2024 and 24 December 2024. Inventory with a fair
value in excess of £623,000 was acquired as part of these two share issues,
and as of 29 October 2025 the Company has sold all of the inventory which it
acquired from DSM.
In December 2024 Provexis and DSM also agreed that the estimated royalty for
the two years ended 31 December 2024 would be settled in equity, which it duly
was as part of the 24 December 2024 share issue. The Company will owe DSM
further royalties for the two years ended 31 December 2026, and the Company
will seek and has forecast in its sensitivity analysis / scenario planning to
settle these royalties in equity as well.
The share issues to DSM have been of direct benefit to the Company's cash
resources and net assets, and they have helped the Company to fund a new
production run of Fruitflow II SD which has just been completed by the
Company's outsourced supply chain partners for Fruitflow.
The Company received delivery of the new batch of Fruitflow II SD in October
2025, two months later than originally envisaged, and it has adequate funds to
pay its outsourced supply chain partners for this new inventory, in cash.
The Company is dealing with numerous sales enquiries from existing and new
customers for further direct sales of Fruitflow in 2026 and beyond, in which
favourable context the Company is now planning with its outsourced supply
chain partners to undertake at least three further production runs of
Fruitflow II SD in the next twelve months. The magnitude and timing of these
production runs will be determined with reference to (i) estimated customer
demand over the subsequent 12 to 18 months, (ii) the comparative costs and
timing of a potential production run for a new batch of material and (iii) the
Company's financial resources at that time.
The new production runs are likely to require a significant cash outlay, as
the Company is seeking by necessity to hold greater stocks of Fruitflow to
keep up with increasing demand for the product.
The Company is in ongoing dialogue with its existing and prospective customers
for Fruitflow II SD, seeking their assistance as best possible with forecast
volume estimates. A considerable degree of uncertainty is inherent in the
forecasting process, which is subject to existing and new customers' changing
plans, requirements and regulatory progress, and inevitably there is a wide
range of possible outcomes in terms of overall forecast demand.
The production process for Fruitflow II SD takes place in two stages, which
need to be booked with its outsourced supply chain partners well in advance of
production taking place. The Company is in close dialogue with all key parties
in its supply chain for Fruitflow, to include: (i) maximum capacity planning;
(ii) production cost and other efficiencies; and (iii) the potential
requirement for much larger batches of Fruitflow II SD to be made at
relatively short notice.
With regards to sensitivity analysis, management have prepared scenario
planning to stress-test potential impacts on the cash position of the
business, which have included (i) different revenue outcomes, (ii)
interruption of trade, (iii) no sales growth, (iv) customer failure, and (v)
the possible need to pay the remaining royalties due to DSM for the two years
ended 31 December 2026 in cash and not shares. In each of these downside
stress tests there are a number of mitigating actions that could be taken.
In the coming months, based on its current level of cash, the Group may
therefore need to raise further equity finance or potentially new loan
finance, subject in large part to (i) the size / volume of new production runs
of Fruitflow II SD which the Company may need to commission, with larger
production runs inevitably requiring more cash at the outset, (ii) the
different revenue outcomes which may materialise and (iii) negotiations with
DSM, which have yet to be concluded, regarding the royalty payments for the
remaining royalty bearing period to 31 December 2026, which the Company will
seek to pay in shares and not cash. These three inherently uncertain
forecasting issues are together deemed to represent a material uncertainty
related to going concern.
Considering the success of previous fundraisings and the current performance
of the business, the Directors have a reasonable expectation of raising
sufficient additional equity capital or new loan finance to continue in
operational existence for the foreseeable future. The Company is also engaged
in ongoing negotiations with a third party, potentially seeking to hold some
of its future stock requirements on a consignment basis, only paying for the
stock when it was required for sale. For these reasons the Directors continue
to adopt the going concern basis in preparing the Group's and Parent Company's
financial statements.
Basis of consolidation
Subsidiaries are all entities over which the Group has the power to govern the
financial and operating policies generally accompanying a shareholding of more
than one half of the voting rights. Subsidiaries are fully consolidated from
the date on which control is transferred to the Group. They are
de-consolidated from the date that control ceases.
The consolidated financial information presents the results of the Company and
its subsidiaries, Provexis Nutrition Limited, Provexis Natural Products
Limited, Provexis (IBD) Limited and Provexis Ireland Limited as if they formed
a single entity ('the Group'). All subsidiaries share the same reporting date,
31 March, as Provexis plc. All intra group balances are eliminated in
preparing the financial statements. Provexis Ireland Limited commenced trading
in April 2024.
Non-controlling interest
Profit or loss and each component of other comprehensive income are attributed
to the owners of the parent and to the non-controlling interests. Total
comprehensive income is attributed to the owners of the parent and the
non-controlling interests even if this results in the non-controlling
interests having a deficit balance.
Revenue
(i) Performance obligations and timing of revenue recognition
The group's revenue is primarily derived from selling goods, with revenue
recognised at a point in time when control of the goods has transferred to the
customer. Revenue from sales to external customers is recognised when goods
are despatched.
There is limited judgment needed in identifying the point at which these
performance obligations are satisfied.
(ii) Determining the transaction price
The amount of revenue to be earned is determined by reference to (i) the fixed
price contracts which the group has with its customers, in respect of the
direct sale of goods to these customers and (ii) the provisions of the group's
profit-sharing Alliance Agreement with DSM, which is based on DSM's fixed
price contracts with their customers. Variable consideration relating to
volume rebates has been constrained in estimating contract revenue in order
that it is highly probable there will not be a future reversal in the amount
of revenue recognised when the amount of volume rebates has been determined.
(iii) Allocating amounts to performance obligations
For most contracts, there is a fixed unit price for each product sold, with
discounts given for bulk orders placed at a specific time. Therefore, there is
no judgement involved in allocating the contract price to each unit ordered in
such contracts (it is the total contract price divided by the number of units
ordered).
Sales rebate and discount reserves are established based on management's best
estimate of the amounts necessary to meet claims by customers in respect of
these rebates and discounts. A refund liability is made at the time of sale
and updated at the end of each reporting period for changes in circumstances.
(iv) Practical exemptions
The Group has taken advantage of the practical exemption not to account for
significant financing components where the time difference between receiving
consideration and transferring control of goods to its customer is less than
one year.
Segment reporting
The Group determines and presents operating segments based on the information
that internally is provided to the Board of Directors, which is the Group's
'chief operating decision maker' ('CODM').
An operating segment is a component of the Group that engages in business
activities from which it may earn revenues and incur expenses, including
revenues and expenses that relate to transactions with any of the Group's
other components. An operating segment's operating results are reviewed
regularly by the CODM to make decisions about resources to be allocated to the
segment and assess its performance, and for which discrete financial
information is available.
Segment results that are reported to the Group Board include items directly
attributable to a segment as well as those that can be allocated on a
reasonable basis.
Segment capital expenditure is the total cost incurred during the period to
acquire property, plant and equipment, and intangible assets.
Use of non-GAAP profit measure - underlying operating profit
The Directors believe that the operating loss before share-based payments
measure provides additional useful information for shareholders on underlying
trends and performance. This measure is used for internal performance
analysis. Underlying operating loss is not defined by IFRS and therefore may
not be directly comparable with other companies' adjusted profit measures. It
is not intended to be a substitute for, or superior to IFRS measurements of
profit.
A reconciliation of underlying operating profit to statutory operating profit
is set out in the Strategic Report.
Intangible assets
Research and development
Expenditure incurred on the development of internally generated products is
capitalised if it can be demonstrated that:
● It is technically feasible to develop the product for it
to be sold;
● Adequate resources are available to complete the
development;
● There is an intention to complete and sell the product;
● The Group is able to sell the product;
● Sale of the product will generate future economic
benefits; and
● Expenditure on the project can be measured reliably.
The value of the capitalised development cost is assessed for impairment
annually. The value is written down immediately if impairment has occurred.
Development costs are not being amortised as income has not yet been realised
from the underlying technology. Development expenditure, not satisfying the
above criteria, and expenditure on the research phase of internal projects is
recognised in profit and loss as incurred.
Patents and trade marks
The costs incurred in establishing patents and trade marks are either expensed
or capitalised in accordance with the corresponding treatment of the
development expenditure for the product to which they relate.
Impairment of non- financial assets
Assets that have a finite useful life but that are not yet in use and are
therefore not subject to amortisation or depreciation are tested annually for
impairment. Assets that are subject to amortisation are reviewed for
impairment annually and when events or circumstances suggest that the carrying
amount may not be recoverable, an impairment loss is recognised for the amount
by which the asset's carrying amount exceeds its recoverable amount.
If the recoverable amount of an asset is estimated to be less than its
carrying amount, the carrying amount of the asset is reduced to its
recoverable amount. An impairment loss is recognised immediately in profit and
loss, unless the relevant asset is carried at a revalued amount, in which case
the impairment loss is treated as a revaluation decrease.
Where an impairment loss subsequently reverses, the carrying amount of the
asset is increased to the revised estimate of its recoverable amount, but so
that the increased carrying amount does not exceed the carrying amount that
would have been determined had no impairment loss been recognised for the
asset in prior periods. A reversal of an impairment loss is recognised
immediately in the statement of comprehensive income, unless the relevant
asset is carried at a revalued amount, in which case the reversal of the
impairment loss is treated as a revaluation increase. Impairment losses on
goodwill are not reversed.
Inventories
Inventories, representing finished goods, are stated at the lower of cost and
net realisable value. Cost comprises all costs of purchase, costs of
conversion and other costs incurred in bringing the inventories to their
present location and condition. Cost is calculated on a first in, first out
basis.
Net realisable value is based on estimated selling price less further costs to
completion and disposal. A charge is made to the income statement for slow
moving inventories. The charge is reviewed at each reporting date.
Financial instruments
Financial assets
The Group's financial assets are comprised of 'trade and other receivables'
and 'cash and cash equivalents'. They are recognised initially at their fair
value and subsequently at amortised cost using the effective interest method,
less provision for impairment. Impairment provisions for trade and other
receivables are recognised based on the simplified approach within IFRS 9
using a provision matrix in the determination of lifetime expected credit
losses.
Financial liabilities
The Group's financial liabilities comprise 'trade and other payables' and
'borrowings'. These are recognised initially at fair value and subsequently at
amortised cost.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and in hand.
Government grants
Government grants are recognised when there is reasonable assurance that the
grant will be received and the Group will comply with all attached conditions.
Government grants are recognised in the statement of comprehensive income in
the same period to which the costs that they are intended to compensate are
expensed.
Taxation
Current tax is provided at amounts expected to be recovered or to be paid
using the tax rates and tax laws that have been enacted or substantively
enacted at the reporting date.
When research and development tax credits are claimed they are recognised on
an accruals basis and are included as other income.
Deferred tax assets and liabilities are recognised where the carrying amount
of an asset or liability on the statement of financial position differs from
its tax base, except for differences arising on:
· The initial recognition of an asset or liability in a transaction
which is not a business combination and at the time of the transaction affects
neither accounting or taxable profit; and
· Investments in subsidiaries where the Group is able to control
the timing of the reversal of the difference and it is probable that the
difference will not reverse in the foreseeable future.
Recognition of deferred tax assets is restricted to those instances where it
is probable that taxable profits will be available against which the
difference can be utilised.
The amount of the asset or liability is determined using tax rates that have
been enacted or substantively enacted by the reporting date and are expected
to apply when the deferred tax liabilities/(assets) are settled/(recovered).
Deferred tax balances are not discounted.
Deferred tax assets and liabilities are offset when the Group has a legally
enforceable right to offset current tax assets and liabilities and the
deferred tax assets and liabilities relate to taxes levied by the same tax
authority on either:
· The same taxable Group Company; or
· Different Group entities which intend to settle current tax
assets and liabilities on a net basis, or to realise the assets and settle the
liabilities simultaneously, on each future period in which significant amounts
of deferred tax assets or liabilities are expected to be settled or recovered.
Foreign currency translation
Foreign currency transactions are translated into the functional currency
using the exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of such transactions
and from the translation at period end exchange rates of monetary assets and
liabilities denominated in foreign currencies are recognised in profit and
loss
Benefits for Directors and consultants
(i) Defined contribution plans
The Group provides retirement benefits to the Executive Directors, who are the
Group's only employees. The assets of these schemes are held separately from
those of the Group in independently administered funds. Contributions made by
the Group are charged to the statement of comprehensive income in the period
in which they become payable.
(ii) Accrued holiday pay
Provision has been made at the balance sheet date for holidays accrued but not
taken at the salary of the relevant employee at that date.
(iii) Share-based payment transactions for Directors and consultants
The Group operates an equity-settled, share-based compensation plan. Vesting
conditions are service conditions and performance conditions only. Where share
options are awarded to employees and others providing similar services, the
fair value of the options at the date of grant is charged to profit and loss
over the vesting period. Non-market vesting conditions are taken into account
by adjusting the number of equity instruments expected to vest at each
reporting date so that, ultimately, the cumulative amount recognised over the
vesting period is based on the number of options that eventually vest.
If non-market related terms and conditions of options are modified before they
vest, the number of instruments expected to vest at each reporting date, and
therefore the cumulative charge, is amended accordingly. Where equity
instruments are granted to persons other than employees and others providing
similar services, profit and loss is charged with the fair value of goods and
services received.
The proceeds received when options are exercised, net of any directly
attributable transaction costs, are credited to share capital (nominal value)
and the remaining balance to share premium.
Other share-based payment transactions
The fair value of equity-settled share payments made in exchange for goods and
services received by the Group, outside of the Group's share-based
compensation plan, is determined at the date the payment is made. The nature
of the payment is assessed, and the fair value of the payment is either
capitalised or charged to the consolidated statement of comprehensive income.
National insurance on share options
All employee option holders sign statements that they will be liable for any
employers national insurance arising on the exercise of share options.
Interest income
Interest income is recognised on a time-proportion basis using the effective
interest rate method.
Critical accounting estimates and judgements
The preparation of financial statements in conformity with IFRSs requires the
use of certain critical accounting estimates and assumptions that affect the
reported amounts of assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period.
Estimates and judgements are continually made and are based on historic
experience and other factors, including expectations of future events that are
believed to be reasonable in the circumstances.
As the use of estimates is inherent in financial reporting, actual results
could differ from these estimates. The Directors believe the following to be
the key areas of estimation and judgement:
(i) Research and development
Under IAS 38 Intangible Assets, development expenditure which meets the
recognition criteria of the standard must be capitalised and amortised over
the useful economic lives of intangible assets from product launch.
(ii) Share-based payments
The Group operates an equity-settled, share-based compensation plan. The
charge for share-based payments is determined based on the fair value of
awards at the date of grant partly by use of a Binomial / Black-Scholes
convergence pricing model which require judgements to be made regarding
expected volatility, dividend yield, risk free rates of return and expected
option lives. The inputs used in these pricing models to calculate the fair
values are set out in note 16.
2. Financial risk management
2.1 Financial risk factors
The Group's activities inevitably expose it to a variety of financial risks:
market risk (including currency risk, cash flow interest rate risk and fair
value interest rate risk), credit risk and liquidity risk.
It is Group policy not to enter into speculative positions using complex
financial instruments. The Group's primary treasury objective is to minimise
exposure to potential capital losses whilst at the same time securing
favourable market rates of interest on Group cash deposits using money market
deposits with banks. Cash balances used to settle the liabilities from
operating activities are also maintained in current accounts which earn
interest at variable rates.
(a) Market risk
Foreign exchange risk
The Group's sales of Fruitflow are primarily denominated in Euros, and the
cost of goods for Fruitflow is primarily denominated in and incurred in Euros.
Where customer or supplier transactions of more than £25,000 total value are
to be settled in foreign currencies consideration is given to settling the
sums to be received or paid through foreign exchange conversion at the outset
of the transactions to minimise the risk of adverse currency fluctuations.
The Group analyses its foreign exchange exposure on a dynamic basis throughout
the year, and in mitigation of the foreign exchange risk it is able to change
its pricing to customers, hence the overall foreign exchange risk is not
considered to be material.
Cash flow and fair value interest rate risk
The Group's interest rate risk arises from medium term and short term money
market deposits. Deposits which earn variable rates of interest expose the
Group to cash flow interest rate risk. Deposits at fixed rates expose the
Group to fair value interest rate risk.
The Group analyses its interest rate exposure on a dynamic basis throughout
the year.
(b) Credit risk
Credit risk arises from cash and cash equivalents and deposits with banks and
financial institutions as well as credit exposure in relation to outstanding
receivables. Group policy is to place deposits with institutions with
investment grade A2 or better (Moody's credit rating) and deposits are made in
sterling only. The Group does not expect any losses from non-performance by
these institutions. Management believes that the carrying value of outstanding
receivables and deposits with banks represents the Group's maximum exposure to
credit risk.
(c) Liquidity risk
Liquidity risk arises from the Group's management of working capital, it is
the risk that the Group will encounter difficulty in meeting its financial
obligations as they fall due. Prudent liquidity risk management implies
maintaining sufficient cash and cash equivalents and management monitors
rolling forecasts of the Group's liquidity on the basis of expected cash flow.
The Group had trade and other payables at the statement of financial position
date of £239,621 (2024: £307,448) as disclosed in note 13.
2.2 Capital risk management
The Group considers its capital to comprise its ordinary share capital, share
premium, merger reserve and accumulated retained earnings as disclosed in the
consolidated statement of financial position.
The Group remains funded exclusively by equity capital. The Group's objectives
when managing capital are to safeguard the Group's ability to continue as a
going concern in order to provide returns for equity holders of the Company
and benefits for other stakeholders and to maintain an optimal capital
structure to reduce the cost of capital.
3. Segmental reporting
The Group's operating segments are determined based on the Group's internal
reporting to the Chief Operating Decision Maker (CODM). The CODM has been
determined to be the Board of Directors as it is primarily responsible for the
allocation of resources to segments and the assessment of performance of the
segments. The performance of operating segments is assessed on revenue.
The CODM uses revenue as the key measure of the segments' results as it
reflects the segments' underlying trading performance for the financial period
under evaluation. Revenue is reported separately to the CODM and all other
reports are prepared as a single business unit.
Year ended Year ended
31 March 31 March
2025 2024
£ £
Fruitflow II SD ingredient 1,170,939 651,845
Fruitflow+ Omega 3 121,305 150,119
1,292,244 801,964
4. Loss from continuing operations
Year ended Year ended
31 March 31 March
2025 2024
£ £
Loss from continuing operations is stated after charging:
Research, patent and trade mark costs 325,625 301,722
Foreign exchange losses 3,652 4,696
Equity-settled share-based payment expense:
Share-based payment charges - share options and warrants 168,317 121,051
Total share-based payment charges 168,317 121,051
The total fees of the Group's auditors, and the Group's former auditors for
services provided are analysed below:
Year ended Year ended
31 March 31 March
2025 2024
£ £
Audit services
Parent company 12,000 12,000
Subsidiaries 18,000 14,000
Tax services - compliance
Parent company - -
Subsidiaries - -
Other services
iXBRL services - -
Total fees 30,000 26,000
5. Wages and salaries
The average monthly number of persons, including all Directors, employed or
engaged under contracts for services by the Group during the year was as
follows:
Year ended Year ended
31 March 31 March
2025 2024
Directors 3 3
3 3
Their aggregate emoluments were:
Year ended Year ended
31 March 31 March
2025 2024
£ £
Wages and salaries 229,728 266,562
Social security costs 20,382 25,465
Pension and other staff costs 23,213 23,896
Total cash settled emoluments 273,323 315,923
Share-based payment remuneration charge: equity settled 84,463 66,922
Total emoluments 357,786 382,845
6. Directors' remuneration
Year ended Year ended
31 March 31 March
2025 2024
£ £
Directors
Aggregate emoluments 229,728 266,562
Company pension contributions 23,213 23,896
252,941 290,458
Share-based payment remuneration charge: equity settled 84,463 66,922
Total Directors' emoluments 337,404 357,380
Emoluments disclosed above include the following amounts in respect of the
highest paid Director:
Year ended Year ended
31 March 31 March
2025 2024
£ £
Aggregate emoluments 166,008 153,408
Company pension contributions 19,601 15,341
Share-based payment remuneration charge: equity settled 51,094 33,461
Total of the highest paid Director's emoluments 236,703 202,210
During the current year and the prior year two Directors participated in
defined contribution pension schemes.
During the current year and the prior year the Directors did not receive any
benefits in kind.
7. Finance income
Year ended Year ended
31 March 31 March
2025 2024
£ £
Finance income
Bank interest receivable 2,334 1,594
2,334 1,594
8. Taxation
Year ended Year ended
31 March 31 March
2025 2024
£ £
Current tax
Overseas subsidiary taxation at 12.5% (8,585) -
Research and development credit - current year 5,502 13,880
Total tax (charge) / credit (3,083) 13,880
The tax assessed for the year is different from the standard rate of
corporation tax in the UK. The differences are explained below:
Year ended Year ended
31 March 31 March
2025 2024
£ £
Loss before tax (449,637) (601,998)
Loss before tax multiplied by the
standard rate of corporation tax in the UK of 25% (2024: 25%) 112,409 150,500
Effects of:
Expenses not deductible for tax purposes (42,079) (30,263)
Unutilised tax losses and other deductions arising in the year (87,500) (120,237)
Research and development credit - current year 5,502 13,880
Overseas tax rate - Ireland 8,585 -
Total taxation (charge) / credit for the year (3,083) 13,880
At 31 March 2025 the Group UK tax losses to be carried forward are estimated
to be £21,327,300 (2024: £20,972,560). The UK corporation tax rate for the
year was 25.0% (2024: 25.0%). The tax losses represent deferred tax assets
amounting to £5,331,825, calculated at 25% (2024: £5,243,140, calculated at
25%), which have not been recognised on the basis that their future economic
benefit is not probable.
The Group submits claims for R&D tax credits in respect of its research
and development activities for potential new patents arising from scientific
research performed by group employees and the group's partners. Whilst the
Board is confident of recovery of the estimated R&D tax credit, there is
no certainty that the receivable will be recoverable until HMRC have approved
the claim and the enquiry window is closed. However, based on the group's
history of successful claims over a number of years, the Board is satisfied
that the tax receivable is recoverable and appropriately recorded.
9. Earnings per share and diluted earnings per share
Basic earnings per share amounts are calculated by dividing the profit or loss
attributable to owners of the parent by the weighted average number of
ordinary shares in issue during the financial year.
The loss attributable to equity holders of the Company for the purpose of
calculating the fully diluted loss per share is identical to that used for
calculating the basic loss per share. The exercise of share options, disclosed
in note 16, would have the effect of reducing the loss per share and is
therefore anti-dilutive under the terms of IAS 33 'Earnings per Share'.
Basic and diluted loss per share amounts are in respect of all activities.
Year ended Year ended
31 March 31 March
2025 2024
Loss and total comprehensive loss
for the year attributable to owners of the parent - £ 452,720 586,243
Weighted average number of shares 2,284,370,301 2,217,821,523
Basic and diluted loss per share - pence 0.02 0.03
10. Intangible assets
Goodwill Development costs Total
£ £ £
Cost
At 1 April 2024 7,265,277 158,166 7,423,443
At 31 March 2025 7,265,277 158,166 7,423,443
Amortisation and Impairment
At 1 April 2024 7,265,277 158,166 7,423,443
At 31 March 2025 7,265,277 158,166 7,423,443
Net book value
At 31 March 2025 - - -
At 31 March 2024 - - -
Cost
At 1 April 2023 7,265,277 158,166 7,423,443
At 31 March 2024 7,265,277 158,166 7,423,443
Amortisation and Impairment
At 1 April 2023 7,265,277 158,166 7,423,443
At 31 March 2024 7,265,277 158,166 7,423,443
Net book value
At 31 March 2024 - - -
At 31 March 2023 - - -
Development costs represent costs incurred in registering patents that meet
the capitalisation criteria set out in IAS 38, see also note 1.
11. Inventories
31 March 31 March
2025 2024
£ £
Finished goods 202,352 136,520
202,352 136,520
There are no provisions included within inventories in relation to the
impairment of inventories (2024: £Nil).
During the year inventories of £618,470 (2024: £389,078) were recognised as
an expense within cost of goods sold.
12. Trade and other receivables
31 March 31 March
2025 2024
£ £
Amounts receivable within one year:
Trade receivables 1,796 19,443
Other receivables 57,837 91,701
Total financial assets other than cash 59,633 111,144
and cash equivalents classified as loans and receivables
Prepayments 22,569 14,335
Total trade and other receivables 82,202 125,479
Trade and other receivables do not contain any impaired assets.
Trade receivables represent debts due for the sale of goods to customers, and
other receivables represent recoverable VAT.
The Directors consider that the carrying amount of these receivables
approximates to their fair value. All amounts shown under receivables fall due
for payment within one year. The Group does not hold any collateral as
security.
The Group applies the IFRS 9 simplified approach to measuring expected credit
losses using a lifetime expected credit loss provision for trade receivables
and contract assets. To measure expected credit losses on a collective basis,
trade receivables and contract assets are grouped based on similar credit risk
and aging.
Any impairment review based on the Group's expected loss rates is currently
deemed to be immaterial to the Group.
At 31 March 2025 trade receivables of £Nil (2024: £Nil) were more than 60
days past due, and there were no lifetime expected credit losses of the full
value of trade receivables (2024: £Nil).
13. Trade and other payables
31 March 31 March
2025 2024
£ £
Trade payables 27,786 20,842
Accruals 202,607 275,035
Total financial liabilities measured at amortised cost 230,393 295,877
Other taxes and social security 9,228 11,571
Total trade and other payables 239,621 307,448
The Directors consider that the carrying amount of these liabilities
approximates to their fair value.
All amounts shown fall due within one year.
14. Deferred tax
Deferred tax is calculated in full on temporary differences under the
liability method using a tax rate of 25% (2024: 25%).
No amounts in respect of deferred tax were recognised in profit and loss from
continuing operations or charged / credited to equity for the current or prior
year.
The UK corporation tax rate for the year was 25.0% (2024: 25.0%).
Deferred tax assets amounting to £5,331,825 (2024: £5,243,140) have not been
recognised on the basis that their future economic benefit is not probable.
Assuming a prevailing tax rate of 25% (2024: 25%) when the timing differences
reverse, the unrecognised deferred tax asset comprises:
31 March 31 March
2025 2024
£ £
Depreciation in excess of capital allowances - -
Unutilised tax losses 5,331,825 5,243,140
5,331,825 5,243,140
15. Share capital
Allotted, called up and fully paid Ordinary Ordinary
0.1p shares 0.1p shares
£ number
At 31 March 2024 2,217,822 2,217,821,523
Issue of shares - 5 April 2024 45,123 45,123,732
Issue of shares - 24 December 2024 82,946 82,945,984
At 31 March 2025 2,345,891 2,345,891,239
Allotted, called up and fully paid Ordinary Ordinary
0.1p shares 0.1p shares
£ number
At 31 March 2023 2,217,822 2,217,821,523
At 31 March 2024 2,217,822 2,217,821,523
On 28 March 2024 the Company announced that it had agreed to issue 45,123,732
new ordinary shares of 0.1p each in the Company to dsm-firmenich in part
satisfaction of an inventory purchase, with the remainder of the inventory
purchase to be paid for in cash.
The 45,123,732 new ordinary shares were admitted by the London Stock Exchange
to trading on AIM on 5 April 2024.
On 18 December 2024 the Company announced that it had agreed to issue
82,945,984 new ordinary shares of 0.1p each in the Company to dsm-firmenich in
satisfaction of an inventory purchase and estimated royalty payment.
The 82,945,984 new ordinary shares were admitted by the London Stock Exchange
to trading on AIM on 24 December 2024.
16. Share options and warrants
The Company's share option scheme for employees ('the Provexis 2005 share
option scheme') was adopted in June 2005. Under the scheme, options to
purchase ordinary shares are granted by the Board of Directors, normally
subject to the exercise price of the option being not less than the market
value at the grant date.
Share options typically vest after a period of 3 years and the vesting
schedule is subject to predetermined overall company selection criteria. In
the event that an option holder's employment is terminated, the option may not
be exercised unless the Board of Directors so permits. Share options expire 10
years from the date of grant.
Share options are exercisable between 3 and 10 years from date of grant and
are subject to performance criteria, including share price appreciation. The
Company believes the grant of options closely aligns the interests of the
option holders with those of shareholders.
The fair values of options granted are estimated at the date of grant in
accordance with IFRS 2, using a Binomial / Black-Scholes convergence model.
At 31 March 2025 the number of ordinary shares subject to options granted over
the 2005 share option scheme was:
EMI options
31 March 2025 31 March 2024
Weighted average exercise price Number Weighted average exercise price Number
(pence) (pence)
Outstanding at the beginning of the year 0.83 34,000,000 0.88 54,635,000
Granted during the year 0.35 16,253,000 - -
Lapsed during the year - - 0.97 (20,635,000)
Outstanding at the end of the year 0.67 50,253,000 0.83 34,000,000
The exercise price of EMI options outstanding at the end of the year ranged
between 0.83p and 0.35p (2024: the exercise price was 0.83p) and their
weighted average contractual life was 8.4 years (2024: 8.8 years).
Of the total number of EMI options outstanding at the end of the year, none of
the EMI options (2024: none) had vested and were exercisable at the end of the
year.
Unapproved options
31 March 2025 31 March 2024
Weighted Number Weighted Number
average average
exercise price exercise price
(pence) (pence)
Outstanding at the beginning of the year 0.55 154,500,000 0.58 166,865,000
Granted during the year 0.25 39,747,000 - -
Lapsed during the year 0.67 (10,000,000) 0.97 (12,365,000)
Outstanding at the end of the year 0.48 184,247,000 0.55 154,500,000
The exercise price of unapproved options outstanding at the end of the year
ranged between 0.20p and 0.92p (2024: 0.30p and 0.92p) and their weighted
average contractual life was 5.3 years (2024: 4.7 years).
Of the total number of unapproved options outstanding at the end of the year,
128,500,000 (2024: 128,500,000) had vested and were exercisable at the end of
the year. Their weighted average exercise price was 0.50 pence (2024: 0.49
pence).
Warrants
31 March 2025 31 March 2024
Weighted Number Weighted Number
average average
exercise price exercise price
(pence) (pence)
Outstanding at the beginning of the year - - - -
Granted during the year 0.20 58,730,000 - -
Outstanding at the end of the year 0.20 58,730,000 - -
The exercise price of the warrants outstanding at the end of the year was
0.20p (2024: Nil warrants) and their weighted average contractual life was 9.8
years (2024: Nil warrants).
None of the warrants outstanding at the end of the year had vested and were
exercisable at the end of the year (2024: None).
The fair values of the options and the warrants have been estimated at the
date of grant using a Binomial / Black-Scholes convergence model, with an
expected volatility for the options and warrants granted in the year ended 31
March 2025 of 73%, an expected dividend yield of 0%, a 4.27% risk free rate of
return and a 10 year expected option and warrant life (2024: NIL options
granted).
The expected life of the options is based on historical data and is not
necessarily indicative of the exercise patterns that may occur. The expected
volatility reflects the assumption that the historical volatility
is indicative of future trends, which may not necessarily be the actual
outcome.
The total share-based payment charge for the year relating to employee
share-based payment plans and warrants was £168,317 (2024: £121,051) all of
which related to equity settled share-based payment transactions.
17. Reserves
Details of movements in reserves are provided as part of the consolidated
statement of changes in equity.
The following describes the nature and purpose of each reserve within total
equity:
Share premium Amount subscribed for share capital in excess of nominal value, less the
related costs of share issues.
Merger reserve The merger reserve arose on the reverse takeover in 2005 of Provexis Natural
Products Limited (formerly Provexis Limited) by Provexis plc through a share
for share exchange and on the issue of shares for the acquisition of SiS
(Science in Sport) Limited in 2011. SiS (Science in Sport) Limited was
demerged from Provexis with effect from 9 August 2013 by way of a capital
reduction demerger and transferred to a newly incorporated parent company,
Science in Sport plc.
Retained earnings Cumulative net gains and losses recognised in the consolidated statement of
comprehensive income.
18. Pension costs
The pension charge represents contributions payable by the Group to
independently administered funds which for continuing operations during the
year ended 31 March 2025 amounted to £23,213 (2024: £23,896). Employee and
employer pension contributions payable but not yet paid at 31 March 2025
totalled £Nil (2024: £Nil).
19. Related party transactions
Key management compensation
The Directors represent the key management personnel. Details of their
compensation and share options are given in note 6.
20. Events after the reporting date
No material post balance sheet events occurred after the end of the period.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END FR FKLLLEBLLFBE
Copyright 2019 Regulatory News Service, all rights reservedRecent news on Provexis
See all newsREG - AIM Provexis PLC - Restoration - Provexis plc
AnnouncementREG - Provexis PLC - Final Results
AnnouncementREG - AIM Provexis PLC - Suspension - Provexis PLC
AnnouncementREG - Provexis PLC - Delay in publication of annual accounts
AnnouncementREG - Provexis PLC - Grant of Options and Warrants
Announcement